NCT04207255进行中（未招募）2 期
A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 67
- 试验地点
- 2
- 主要终点
- Disease Control Status
研究概览
简要总结
This is a Phase II study of the investigational drug opaganib. Patients with metastatic castration resistant prostate cancer (mCRPC) who have experienced disease progression while receiving abiraterone or enzalutamide will receive Opaganib at either 250 mg or 500 mg by mouth twice a day continuously. Patients will continue on study drug until the development of progressive disease, intolerable toxicity, withdrawal of patient consent or other event as outlined in patient discontinuation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patient must have mCRPC. Each patient must have:
- •Tissue diagnosis documented by pathology report, or clinic note attesting to same.
- •Radiographically-demonstrated metastases
- •Patients must have adenocarcinoma, or ductal carcinoma, or combinations of these two entities
- •Voluntary, signed and dated, institutional review board (IRB)-approved informed consent form in accordance with regulatory and institutional guidelines.
- •Documented progression during treatment with enzalutamide or abiraterone, as determined by the enrolling investigator.
- •Testosterone level documented to be less than 50ng/
- •18 years of age or older.
- •ECOG performance status of 0-
- •Acceptable liver function:
- •Bilirubin ≤ 1.5 times upper limit of normal (CTCAE Grade 1 baseline)
- •AST (SGOT) & ALT (SGPT) ≤ 3 x ULN (CTCAE Grade 1 baseline)
- •Subjects with Gilbert's syndrome may be included if the total bilirubin is <3x ULN and the direct bilirubin is within normal limits
- •Acceptable kidney function indicated by serum creatinine ≤ 1.5 X ULN (CTCAE Grade 1 baseline)
- •Acceptable hematologic status:
- •Absolute neutrophil count ≥ 1000 cells/mm3,
- •Platelet count ≥ 75,000 (plt/mm3) (CTCAE Grade 1 baseline)
- •Hemoglobin ≥ 9.0 g/dL.
- •Fasting blood glucose of <165mg/dL
- •Urinalysis: no clinically significant abnormalities
- •International normalized ratio (INR) ≤1.7
- •Well-controlled blood pressure as determined by the treating investigator
- •Patients requiring narcotic analgesics must be on stable doses for at least 2 weeks prior to study entry.
排除标准
- •New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.
- •Underlying psychiatric disorder requiring hospitalization within the last two years.
- •Clinically significant neurological disorder (Parkinson's disease, dementia, multiple sclerosis), as determined by the enrolling investigator.
- •Active, uncontrolled bacterial, viral or fungal infection, requiring systemic therapy.
- •Treatment with radiation therapy, surgery, or investigational therapy within 28 days prior to registration.
- •Unwillingness or inability to comply with procedures required in this protocol.
- •Serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator.
- •Patients who are receiving coumadin, apixaban, argatroban or rivaroxaban. Patients who are receiving other drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes that cannot be stopped at least 7 days or 5 half-lives (whichever is longer) before starting treatment with opaganib may be treated on this study with careful monitoring for toxic effects or loss of efficacy of the relevant drug. A list of commonly used drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes with the half-life of each drug identified, is included as an Appendix C.
- •Patients who are currently participating in any other clinical trial of an investigational product.
- •Other primary malignancy requiring systemic treatment within past 5 years except carcinoma in situ of the cervix or urinary bladder or non-melanoma skin cancer.
- •Any other mental incapacitation or psychiatric illness that would preclude study participation, as determined by the enrolling investigator.
- •Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
研究组 & 干预措施
Cohort 2: Opaganib with abiraterone
Experimental
干预措施: Abiraterone (Drug)
Cohort 3: Opaganib with enzalutamide
Experimental
干预措施: Opaganib (Drug)
Cohort 3: Opaganib with enzalutamide
Experimental
干预措施: Enzalutamide (Drug)
Cohort 1a: Opaganib with abiraterone
Experimental
干预措施: Abiraterone (Drug)
Cohort 1a: Opaganib with abiraterone
Experimental
干预措施: Opaganib (Drug)
Cohort 2: Opaganib with abiraterone
Experimental
干预措施: Opaganib (Drug)
Cohort 1b: Opaganib with enzalutamide
Experimental
干预措施: Enzalutamide (Drug)
Cohort 1b: Opaganib with enzalutamide
Experimental
干预措施: Opaganib (Drug)
结局指标
主要结局
Disease Control Status
时间窗: 113 days
Stable disease or better according to Prostate Cancer Working Group 3 (PCWG3) criteria after four cycles of treatment
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study of Pazopanib With CAPEOX in AGC PatientsGastric CancerNCT01130805Samsung Medical Center66
已完成
不适用
Single Dose Radiotherapy (SDRT) in Oligometatstasis AblationMetastatic CancerNCT03543696Fundacao Champalimaud150
终止
2 期
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination DeficiencyMetastatic Castration-Resistant Prostate Cancer (mCRPC)Homologous Recombination Deficiency (HRD)NCT03712930BeiGene13
终止
2 期
Olaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaCastration-Resistant Prostate CarcinomaProstate AdenocarcinomaNCT04951492University of Washington2
尚未招募
2 期
PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersMetastatic Breast Cancer in Germline-PALB2 Mutations CarriersNCT05232006Assistance Publique - Hôpitaux de Paris12